Steve Burrill , CEO , Burrill & Company, USA
　G. Steven Burrill has been involved in the growth and prosperity of the biotechnology industry for over 35 years. An early pioneer, Mr. Burrill is one of the original architects of the industry and one of its most avid and sustained developers. He currently serves as Chairman of the Boards of Pharmasset, and Genomics; and is a member of the Boards of Directors of Catalyst Biosciences, DepoMed (Amex: DMI), Targacept, and Third Wave Technologies (NASDAQ: TWTI). In 2002, Mr. Burrill was recognized as the biotech investment visionary by the prestigious Scientific American magazine (The Scientific American 50).

Whaijen Soo, M.D., Ph.D. Senior Vice President, Medical Research Biogenidec, Inc.
　As Senior Vice President of Medical Research at Biogen Idec, Inc, Dr. Soo has been responsible for the worldwide clinical development of all drugs in the Biogen Idec portfolio. Functionally, his organization includes clinical development, drug safety and risk management, statistics and data management, and global operations in Cambridge, Massachusetts, San Diego, California, and Maidenhead, UK. Key diseases of focus for biogenidec include multiple sclerosis, rheumatoid arthritis, various hemoatologic malignancies and solid-tumor cancer, other diseases of immuno-dysfunctions such as lupus, Crohn's, severe asthma, as well as neurodegenerative diseases.

Kenneth Fong , Chairman, Kenson Ventures, LLC
　Dr. Kenneth Fong is currently the Chairman of KENSON Ventures, LLC based in Palo Alto, CA. KENSON has 20 biotechnology companies in its investment portfolio.
　Dr. Fong was the founder and CEO of CLONTECH, which develops and markets Molecular Biology products to academic and pharmaceutical laboratories in the US and thirty other countries. The company was selected in 1994, 1995, 1998 and 1999 by San Jose and San Francisco Business Journals as one of the 100 fastest-growing private companies in the Bay Area.

Denis Lucquin , Managing Partner, Sofinnova Inc.
　Denis Lucquin, Managing Partner, joined Sofinnova SA in 1991. For five years, he was in charge of the technology transfer department at the Institut National de la Recherche Agronomique (INRA), France's agricultural research institute. In 1989, he joined the venture capital industry as director of investments at Innolion (Credit Lyonnais). He carried out many investments in France and other European countries in companies such as Nicox, Exonhit, IDM, Neurotech, Innate Pharma, Neuro 3D, Oxford Glycosciences, Oxford Molecular, PPL Therapeutics, Crop Design, Metris Therapeutics, Ablynx and Novexel. He sits on the board of many of these companies. Denis is also a founder of Association France Biotech.